CEBPZ and acute myeloid leukemia: Although CBF-AML carries a relatively favorable prognosis,suboptimal molecular response after induction therapy—defined by persistent MRD at levels >10−3 (or <3-log reduction from baseline)—significantly increases relapse risk in both pediatric and adult patients (36–38).